Physician profile
Holly Mitchell
NPI 1881630622
$8,612.04
in general payments reported to CMS, 2019-2025
54 companies · $1,777 in 2025
The $1,777 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $620 · 2021: $876 · 2022: $1,029 · 2023: $1,392 · 2024: $1,355 · 2025: $1,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,523.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $762.26 | 2019-2023 | Trelegy Ellipta |
| Emd Serono, INC. | $731.29 | 2021-2025 | Mavenclad |
| Novo Nordisk INC | $557.77 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $428.24 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $392.28 | 2019-2025 | Uplizna |
| Biogen, INC. | $386.77 | 2021-2025 | Vumerity, Tysabri, Spinraza |
| Ucb, INC. | $368.21 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Genzyme Corporation | $361.79 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.91 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $301.04 | 2019-2025 | Emgality, Reyvow, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $281.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $276.31 | 2019-2025 | |
| Eisai INC. | $239.78 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.28 | 2019-2024 | Entyvio |
| Supernus Pharmaceuticals, INC. | $227.94 | 2019-2023 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $220.47 | 2025 | |
| Lundbeck LLC | $211.80 | 2022-2025 | Rexulti, Vyepti |
| Abbvie INC. | $197.69 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $195.49 | 2022-2024 | Epidiolex |
| Argenx US, INC. | $190.55 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Biotech, INC. | $180.54 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $154.69 | 2022-2025 | Dupixent |
| Sk Life Science, INC. | $152.97 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $134.42 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ani Pharmaceuticals, INC. | $103.40 | 2022-2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $96.39 | 2021-2025 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $65.03 | 2024-2025 | Apokyn |
| Kyowa Kirin, INC. | $64.65 | 2023-2024 | Nourianz |
| Bayer Healthcare Pharmaceuticals INC. | $62.07 | 2022 | |
| Ardelyx, INC. | $59.17 | 2024-2025 | Ibsrela |
| Avanir Pharmaceuticals, INC. | $58.99 | 2019 | |
| Abiomed | $47.51 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $44.40 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $36.27 | 2025 | Sucraid |
| Otsuka America Pharmaceutical, INC. | $34.87 | 2024-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $33.76 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $33.26 | 2025 | Tascenso Odt, Bafiertam |
| Grifols USA, LLC | $31.89 | 2019 | |
| Horizon Therapeutics Plc | $30.86 | 2022 | |
| Abbott Laboratories | $29.72 | 2019 | |
| Acorda Therapeutics, INC | $29.11 | 2019-2023 | Inbrija |
| Csl Behring | $28.00 | 2025 | Hizentra |
| Octapharma USA, INC. | $27.12 | 2021 | |
| Axsome Therapeutics, INC. | $21.51 | 2025 | Sunosi |
| Medtronic, INC. | $20.86 | 2024 | Intellis Adaptivestim |
| Mylan Institutional INC. | $20.33 | 2023 | Hulio |
| Ge Healthcare | $18.88 | 2025 | |
| Merz Pharmaceuticals, LLC | $18.43 | 2025 | Inbrija |
| Tg Therapeutics, INC. | $17.83 | 2025 | |
| Promius Pharma LLC | $16.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.93 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 2021 | |
| Duchesnay USA Incorporated | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.